IRD (Opus Genetics) ROCE % : -80.35% (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Opus Genetics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Opus Genetics's annualized ROCE % for the quarter that ended in Sep. 2024 was -80.35%.

Opus Genetics ROCE % Historical Data

The historical data trend for Opus Genetics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opus Genetics ROCE % Chart

Opus Genetics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-512.41

-308.78

53.20

-20.75

Opus Genetics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															62.76	-48.91	-64.26	-76.85	-80.35

Opus Genetics ROCE % Calculation

Opus Genetics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-9.974	/	( ( (48.992 - 2.753)	+	(53.948 - 4.042) )	/ 2 )
	=	-9.974	/	( (46.239	+	49.906)	/ 2 )
	=	-9.974	/	48.0725
	=	-20.75 %

Opus Genetics's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-30.104	/	( ( (44.834 - 4.198)	+	(40.389 - 6.089) )	/ 2 )
	=	-30.104	/	( ( 40.636	+	34.3 )	/ 2 )
	=	-30.104	/	37.468
	=	-80.35 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Opus Genetics (NAS:IRD) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Opus Genetics ROCE % Related Terms

Thank you for viewing the detailed overview of Opus Genetics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Opus Genetics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opus Genetics Inc (NAS:IRD) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

R3X1:Germany

Address

37000 Grand River Avenue, Suite 120, Farmington Hills, MI, USA, 48335

Website

https://www.opusgtx.com

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Executives

George Magrath	officer: Chief Executive Officer	37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Ronil A. Patel	officer: SVP, Operations & Bus. Dev.	37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Mina Sooch	director, officer: President and CEO	17199 N. LAUREL PARK DRIVE, SUITE 401, LIVONIA MI 48152
Manuso James S J	director	5130 ROUTE 212, WILLOW NY 12495
Jay Pepose	director	37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Susan Benton	director	3916 VALRICO GROVE DRIVE, VALRICO FL 33594
Rabourn Amy Zaremba	officer: VP of Finance	37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Cam Gallagher	director	6042 CORNERSTONE CT. WEST, SUITE B, SAN DIEGO CA 92121
Alan R Meyer	director
Sean Ainsworth	director	37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Bernhard Hoffmann	officer: VP of Corp. Dev. & Ops & Sec.	37000 GRAND RIVER AVE, SUITE 120, FARMINGTON HILLS MI 48335
Lara Sullivan	director	C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455, ROCKVILLE MD 20850
Ben Gil Price	director	8297 CHAMPIONS GATE BLVD. #444, CHAMPIONS GATE FL 33896
Douglas J Swirsky	officer: President and CFO	C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850
Lisa Nolan	officer: Chief Business Officer	36 ROCKLAND MILLS, ROCKLAND DE 19732